Stock·NYSE·Healthcare
agilon health, inc. (AGL)
- Market cap
- $1.43B
- Dividend yield
- None
- Street target
- $115.00median of 15 analysts
- 52-week range
- $7.48 $133.04
AGL stock forecast today
Where AGL stands today, and what CleaRank Financial AI makes of it.
AGL at a glance
agilon health, inc. (AGL): Hold, 57/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($64.99 and $87.87).
- Earnings AGL beat estimates in 1 of its last 7 quarters, yet fell the next day after every one of them.
- Insiders Insiders bought $352K and made no open-market sales over the last 18 months.
Figures as of October 30, 2026.
CleaRank Financial AI
AGL, or agilon health, inc., receives a Hold rating from CleaRank with a model score of 57/100.
Trend contributes the most to that score, with the price 30.64% above its 200-day average and the 50-day average 35.20% above the 200-day. Valuation is the biggest drag, since the company has no meaningful P/E after losing money. The 50-day average is $87.87 and the 200-day is $64.99, and the price rose 324.50% over the past year.
Only on CleaRank
Figures we compute ourselves from AGL's own price, earnings and insider-filing history. Tap one to see it in context.
AGL stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price below its 50-day average ›
The price of $84.90 is 3.4% below the 50-day simple moving average of $87.87.Price above its 200-day average ›
The price is 30.6% above the 200-day simple moving average of $64.99.50-day average above the 200-day ›
The 50-day average ($87.87) is 35.2% above the 200-day average ($64.99), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 62% of its 52-week range, between $7.48 and $133.04.
AGL share price
Pick a period: each tab shows how far AGL has moved over it, to the last close.
Today's trading
Where AGL sits inside today's range and its 52-week range.
AGL fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/3P/S below the sector median ›
The price-to-sales ratio of 0.24 is 92.9% below the sector median of 3.4.Not profitable over the last 12 months ›
Net income over the last 12 months was -$251.2M on revenue of $5.9B, a net margin of -4.2%.Missed estimates in most recent reports ›
AGL beat the EPS estimate in 1 of its last 7 reports.
Key statistics
The headline figures for AGL.
As of October 30, 2026, AGL trades at $84.90, with a market value of $1.43B and no P/E ratio (its trailing earnings are negative).
What the numbers say
CleaRank Financial AI's reading of AGL's valuation, growth and risks.
A P/E cannot be read for agilon health, inc. (AGL): it is not meaningful, because its earnings per share over the last 12 months are negative. AGL trades at 0.24 times its sales, 92.9% below the sector median of 3.4. The company has a market capitalisation of $1.4B and trailing earnings of -$15.41 a share.
AGL is losing money: its net margin is -4.2% and its operating margin is 1.30%. Revenue grew 7.20% year on year, which leaves it 0.9 percentage points slower than the sector median of 8.1%. Return on equity of -78.94% is below the sector median of 7.3%. Debt-to-equity of 0.15 completes the balance sheet picture.
The August 5, 2026 report showed earnings of $2.15 a share, compared with a $0.27 estimate, which amounts to a beat of 696.30%. Even so, the share price dropped 19.49% in the following session.
The earnings record shows 1 beat in 7 reports, yet the stock fell in the first session after that beat. The August 4, 2025 report stands out among the few before the latest: a miss of 136.84%, after which the stock fell 51.52%. The consensus EPS estimate stands at -$1.79 for this fiscal year and $2.36 for next.
AGL moves about 3.20% on a typical day, based on the 30-day standard deviation of its daily returns, and its beta against the S&P 500 is 3.00. Its price is 36.18% under the 52-week high of $133.04.
AGL against the Healthcare sector
How AGL compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, AGL trades at 0.2408x, far below the sector average of 3.40x.
Return vs XLV: Since May 20, 2025, AGL has gained 36.9% against a gain of 37.3% for XLV.
Performance against XLV
AGL and the Healthcare sector fund over the same days.
Revenue and earnings
How much AGL sells, and how much of it becomes profit.
Revenue growth: Revenue fell 2.1% in FY2025 to $5.9B, from $6.1B a year earlier.
Profit margin: The net margin was -6.6% in FY2025, down from -4.3% the year before.
Loss-making: AGL lost $391M in FY2025.
Earnings reality check
Did AGL beat what analysts expected, and how did the stock react?
Earnings record: AGL beat the analyst estimate in 1 of the last 7 quarters.
Market reaction: The stock fell in the first session after that beat, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 5, 2026after close | $0.27 | $2.15 | +696.30% | -19.49% | -20.02% |
| Feb 25, 2026after close | -$6.85 | -$8.95 | -30.66% | +19.00% | +39.80% |
| Nov 4, 2025after close | -$3.36 | -$6.40 | -90.48% | +4.14% | -14.50% |
| Aug 4, 2025after close | -$2.66 | -$6.30 | -136.84% | -51.52% | -52.45% |
| May 6, 2025after close | $0.16 | -$0.21 | -231.25% | -23.99% | -39.46% |
| Feb 25, 2025after close | -$5.32 | -$6.25 | -17.48% | -7.44% | -12.67% |
| Nov 7, 2024after close | -$2.14 | -$6.98 | -226.17% | -34.05% | -38.71% |
As of October 30, 2026, AGL has beaten the analyst EPS estimate in 1 of its last 7 reported quarters and fell in the first trading session after it; its latest report, on August 5, 2026, came in 696.30% above the estimate and the stock moved -19.49% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AGL AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 44.0, in neutral territory.RSI below 50 ›
An RSI of 44.0 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of AGL
The score, the reasoning behind it, and what could move the price next.
AGL sends a mixed trend signal: at $84.90, it trades 3.38% below its 50-day average of $87.87 but 30.64% above its 200-day average of $64.99. The 50-day average sits 35.20% above the 200-day, though the price itself has slipped under the shorter average. Within its 52-week range of $7.48 to $133.04, the price sits at 62%, 36.18% below the high.
Short-term and long-term signals diverge for agilon health, inc. (AGL). Over the past year the price rose 324.50%, and over the past month it rose 6.67%, yet over the past three months it fell 7.32%. The 14-day RSI sits at 44.0, which is neutral territory, and the MACD line is positive.
Analyst upgrade ›
Bernstein upgraded it to Outperform from Market Perform on September 15, 2026.
Source: Analyst action, Bernstein, September 15, 2026Analyst upgrade ›
Citigroup upgraded it to Neutral from Sell on August 11, 2026.
Source: Analyst action, Citigroup, August 11, 2026
Earnings beat, but the stock fell ›
The August 5, 2026 report beat the EPS estimate by 696.30%, and the share price fell 19.49% in the first session after it.
Source: Earnings report, August 5, 2026
- The two closest levels matter most: the 20-day EMA at $87.72 lies above the price, and the 200-day SMA at $64.99 lies below it.
- With the 14-day RSI at 44.0, momentum is neutral, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- The share price fell 19.49% in the first session after the August 5, 2026 report. AGL has beaten estimates in 1 of the last 7 reports.
The trend is mixed: AGL is above its 200-day average at $64.99 but below its 50-day average at $87.87. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. The nearest levels are the 200-day SMA at $64.99 below and the 20-day EMA at $87.72 above.
AGL's 14-day RSI reads 44.0, which places it in the neutral zone between 40 and 60.
Technical indicators
Momentum and trend for AGL, from its daily closes.
As of October 30, 2026, with AGL at $84.90, its 14-day RSI is 44.0 (neutral territory), its 50-day simple moving average is $87.87 and its 200-day is $64.99.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What AGL moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, AGL's 1-year correlation of daily returns is +0.11 with S&P 500 (SPY), +0.11 with Nasdaq 100 (QQQ), +0.23 with Bitcoin (BTC) and +0.09 with gold (XAU).
AGL price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Fewer than half of analysts rate it a buy ›
5 of 15 analysts rate it a buy or strong buy, 9 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $115.00 is 35.5% above the price.More buy ratings than three months ago ›
5 of 15 rate it a buy now, against 4 of 17 three months ago.
AGL Wall Street View
12-month price targets
The price, $84.90, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 15, 2026 | Bernstein | Upgrade | Outperform |
| Aug 24, 2026 | JP Morgan | Maintains | Underweight |
| Aug 11, 2026 | Wells Fargo | Maintains | Overweight |
| Aug 11, 2026 | Citigroup | Upgrade | Neutral |
| Aug 6, 2026 | Truist Securities | Maintains | Hold |
| Aug 6, 2026 | Benchmark | Maintains | Buy |
As of October 30, 2026, 15 Wall Street analysts cover AGL: 5 rate it a buy or strong buy, 9 a hold and 1 a sell or strong sell. Their 12-month price targets range from $85.00 to $146.00. The median AGL price target is $115.00, 35.5% above the price of $84.90.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
AGL trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
AGL trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
AGL moves about 3.2% a day on average, so a stop can fill well past its level. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much AGL tends to move, against the market and on its own.
AGL price history and drawdowns
AGL's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
0/4Average daily move of 2% or more ›
The price has moved 3.20% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 99.3%, from June 2021 to March 2026; the price is still 92.1% below that peak.Most 1-year holds did not end higher ›
19% of 1-year holding periods in the last 6 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in April 2021 is now worth $1,109, against $19,903 in the S&P 500 (SPY).
AGL Drawdowns & Recovery
As of October 30, 2026, AGL's worst peak-to-trough fall over the period since April 2021 with dividends reinvested was -99.3% (June 2021 to March 2026); it is still 92.1% below that peak, and 19% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into AGL in April 2021 is worth now, against the same amount in the S&P 500.
Against the market: AGL trailed the S&P 500 over this period: $1,108.90 against $19,903.
A $10,000 investment in AGL in April 2021 would be worth about $1,109 today with dividends reinvested, compared with about $19,903 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to AGL, and which have not.
Strongest month, April: an average of +46.23%, up in 2 of 5 years.
Weakest month, November: an average of -21.05%, up in 0 of 5 years.
This month, October: has averaged -13.40%, up in 0 of 5 years. Past seasonality does not repeat on schedule.
Over the last 6 years, AGL's strongest calendar month has been April (average +46.23%, up in 2 of 5 years) and its weakest November (average -21.05%, up in 0 of 5 years).
Average return for each calendar month over the last 6 years, from weekly closing prices with dividends included.
AGL stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in AGL, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 6 years of price history, projects that a $10,000 investment in AGL today could grow to about $6,400 by 2030 in the base case, with a 90th-percentile outcome near $23,056 and a 10th-percentile outcome around $1,777. Projections are statistical simulations, not guarantees.
AGL Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $54.34 for AGL by 2030 in the base case, from $84.90 today (0.6x over 4 years). The 10th-percentile path ends near $15.08. These are outcomes of a Monte Carlo simulation run on AGL's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $40.01 | $75.94 | $144 | |
| 2028 | $27.44 | $67.92 | $168 | |
| 2029 | $20.02 | $60.75 | $184 | |
| 2030 | $15.08 | $54.34 | $196 |
Method: a lognormal simulation of AGL's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
AGL insider trading
What the people running the company have bought and sold.
AGL insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider buying: Insiders bought $352K on the open market.
As of October 30, 2026, AGL insiders reported no open-market sales and 2 open-market purchases worth $352K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 2, 2026 | Silvana Battaglia
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | Sharad S. Mansukani
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | Diana L Mckenzie
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | Karen Mcloughlin
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | Ronald A Williams
Director
|
Grant | 2.1K | - |
| Jun 2, 2026 | John William Wulf
Director
|
Grant | 2.1K | - |
| May 7, 2026 | Timothy Patrick O'Rourke
Chief Executive Officer
|
Grant | 320.0K | - |
| Apr 1, 2026 | Timothy Gertsch
Officer
|
Grant | 10.0K | - |
| Apr 1, 2026 | Jeffrey A Schwaneke
Chief Financial Officer
|
Grant | 75.0K | - |
| Apr 1, 2026 | Benjamin Shaker
Officer
|
Grant | 70.0K | - |
| Apr 1, 2026 | Girish Venkatachaliah
Chief Technology Officer
|
Grant | 28.0K | - |
| Apr 1, 2026 | Denise Zamore
Officer
|
Grant | 50.0K | - |
| Mar 9, 2026 | Benjamin Shaker
Officer
|
Grant | 18.4K | - |
| Mar 9, 2026 | Girish Venkatachaliah
Chief Technology Officer
|
Grant | 18.4K | - |
| Mar 9, 2026 | Denise Zamore
Officer
|
Grant | 5.5K | - |
| Mar 2, 2026 | Benjamin Shaker
Officer
|
Buy | 500.0K | $301.1K |
| Jan 9, 2026 | Jeffrey A Schwaneke
Chief Financial Officer
|
Grant | 600.0K | - |
| Nov 12, 2025 | John William Wulf
Director
|
Buy | 81.0K | $50.9K |
| May 28, 2025 | Silvana Battaglia
Director
|
Grant | 78.7K | - |
| May 28, 2025 | Sharad S. Mansukani
Director
|
Grant | 78.7K | - |
| May 28, 2025 | Diana L Mckenzie
Director
|
Grant | 78.7K | - |
| May 28, 2025 | Karen Mcloughlin
Director
|
Grant | 78.7K | - |
| May 28, 2025 | Ronald A Williams
Director
|
Grant | 78.7K | - |
| May 28, 2025 | John William Wulf
Director
|
Grant | 78.7K | - |
Source: TwelveData, from SEC Form 4 filings
AGL stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.